Thanks to countless medicines in development, there is hope on the horizon to take down diseases of all kinds. From mental illness to cancer, researchers are advancing our knowledge of how these diseases operate and developing new approaches and treatments to fight back.
From advanced biologics to transformative therapies, such as cell and gene therapy, recent advancements have revolutionized our ability to treat, and in some cases cure, some of the most challenging diseases.
Janssen is one among dozens of biopharmaceutical companies working around the clock to identify and develop safe and effective vaccines to prevent COVID-19.
October is Breast Cancer Awareness Month, which each year calls attention to the condition that one in every eight women will face throughout their lifetimes.
Why, when we have seen such progress in our ability to treat other diseases, such as cancer, diabetes and HIV, has progress in Alzheimer's research been so difficult to achieve?
In the United States, 16 diseases are now preventable as a result of childhood vaccines, resulting in an estimated $1.4 trillion in societal costs saved.
Dr. Drevets is a scientist at Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, where he oversees the development of new treatments for mood disorders, such as major depressive disorder, treatment resistant depression and suicidality.
Today, a 20-year-old with HIV can expect to live to the age of 70. Few diseases have seen similar progress, and it's somewhat astounding to see that in just over 30 years, HIV has gone from a death sentence to a chronic medical condition.
Today, Dr. Husseini Manji is the global therapeutic head for neuroscience at Janssen. In this role, he has researched the ways in which psychiatric disorders alter a patient’s cellular systems, resulting in symptoms or negative behaviors.
The need for new cancer treatments is more important than ever, and America's biopharmaceutical companies are boldly leading the way in discovering new breakthroughs.
The introduction of statin therapy nearly 30 years ago transformed the treatment of high cholesterol for many patients, yet some continued to face challenges. Advances over the past decade have provided important treatment options for these patients.